Publicaciones – Grupo DIAMET

  1. Luna-Marco, C., Devos, D., Cacace, J., Fernandez-Reyes, M., Díaz-Pozo, P., Salazar, J. D., Solá, E., Morillas, C., Rocha, M., Víctor, V. M., & Rovira-Llopis, S. (2024). Molecular circadian clock disruption in the leukocytes of individuals with type 2 diabetes and overweight, and its relationship with leukocyte-endothelial interactions. Diabetologia, 67(10), 2316–2328. https://doi.org/10.1007/s00125-024-06219-z.
  2. Rovira-Llopis, S., Luna-Marco, C., Perea-Galera, L., Bañuls, C., Morillas, C., &Victor, V. M. (2024). Circadian alignment of food intake and glycaemic control by time-restricted eating: A systematic review and meta-analysis. Reviews in endocrine & metabolic disorders, 25(2), 325–337. https://doi.org/10.1007/s11154-023-09853-x
  3. Luna-Marco, C., de Marañon, A. M., Hermo-Argibay, A., Rodriguez-Hernandez, Y., Hermenejildo, J., Fernandez-Reyes, M., Apostolova, N., Vila, J., Sola, E., Morillas, C., Rovira-Llopis, S., Rocha, M., &Victor, V. M. (2023). Effects of GLP-1 receptor agonists on mitochondrial function, inflammatory markers and leukocyte-endothelium interactions in type 2 diabetes. Redox biology, 66, 102849. https://doi.org/10.1016/j.redox.2023.102849
  4. Apostolova, N., Vezza, T., Muntane, J., Rocha, M., & Víctor, V. M. (2023). Mitochondrial Dysfunction and Mitophagy in Type 2 Diabetes: Pathophysiology and Therapeutic Targets. Antioxidants& redox signaling, 39(4-6), 278–320. https://doi.org/10.1089/ars.2022.0016
  5. Canet, F., Díaz-Pozo, P., Luna-Marco, C., Fernandez-Reyes, M., Vezza, T., Marti, M., Salazar, J. D., Roldan, I., Morillas, C., Rovira-Llopis, S., Rocha, M., & Víctor, V. M. (2022). Mitochondrial redox impairment and enhanced autophagy in peripheral blood mononuclear cells from type 1 diabetic patients. Redox biology, 58, 102551. https://doi.org/10.1016/j.redox.2022.102551
  6. de Marañón, A. M., Díaz-Pozo, P., Canet, F., Díaz-Morales, N., Abad-Jiménez, Z., López-Domènech, S., Vezza, T., Apostolova, N., Morillas, C., Rocha, M., & Víctor, V. M. (2022). Metformin modulates mitochondrial function and mitophagy in peripheral blood mononuclear cells from type 2 diabetic patients. Redox biology, 53, 102342. https://doi.org/10.1016/j.redox.2022.102342
  7. de Marañón, A. M., Canet, F., Abad-Jiménez, Z., Jover, A., Morillas, C., Rocha, M., &Victor, V. M. (2021). Does Metformin Modulate Mitochondrial Dynamics and Function in Type 2 Diabetic Patients?. Antioxidants& redox signaling, 35(5), 377–385. https://doi.org/10.1089/ars.2021.0019
  8. Apostolova, N., Iannantuoni, F., Gruevska, A., Muntane, J., Rocha, M., &Victor, V. M. (2020). Mechanisms of action of metformin in type 2 diabetes: Effects on mitochondria and leukocyte-endothelium interactions. Redox biology, 34, 101517. https://doi.org/10.1016/j.redox.2020.101517
  9. Pradas, I., Rovira-Llopis, S., Naudí, A., Bañuls, C., Rocha, M., Hernandez-Mijares, A., Pamplona, R., Victor, V. M., &Jové, M. (2019). Metformin induces lipid changes on sphingolipid species and oxidized lipids in polycystic ovary syndrome women. Scientificreports, 9(1), 16033. https://doi.org/10.1038/s41598-019-52263-w
  10. Hernandez-Mijares, A., Rocha, M., Rovira-Llopis, S., Bañuls, C., Bellod, L., de Pablo, C., Alvarez, A., Roldan-Torres, I., Sola-Izquierdo, E., &Victor, V. M. (2013). Human leukocyte/endothelial cell interactions and mitochondrial dysfunction in type 2 diabetic patients and their association with silent myocardial ischemia. Diabetes care, 36(6), 1695–1702. https://doi.org/10.2337/dc12-1224

Mas publicaciones del Grupo